R
Rhythm Pharmaceuticals Inc (RYTM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$107.48
-7.54 (-6.56%)
Market Cap: $7.97B
Last updated: Nov 17, 2026 at 11:06 AM ET
Rhythm Pharmaceuticals Inc (RYTM) Valuation Multiples
Rhythm Pharmaceuticals (RYTM) trades at 26.4x sales and 84.4x book value. Its P/S of 26.4x is below its 5-year median of 31.0x. Its forward P/E is 333.3x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 333.3x |
| Price to sales | 26.4x |
| Price to book | 84.4x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/B is 1554.9% above 5.1x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 26.4x | 31.0x | N/A |
| P/B | 84.4x | 20.6x | 5.1x |
Valuation History
Over the 5 of the 9 year ends shown that have a P/S, its P/S ranged from 26.3x in 2024 to 158.9x in 2021.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $107.04 | 36.8x | 51.5x |
| 2024 | $55.98 | 26.3x | 21.0x |
| 2023 | $45.97 | 34.3x | 16.0x |
| 2022 | $29.12 | 64.8x | 6.2x |
| 2021 | $9.98 | 158.9x | 1.8x |
| 2020 | $29.73 | N/A | 7.9x |
| 2019 | $22.96 | N/A | 3.4x |
| 2018 | $26.88 | N/A | 3.8x |
| 2017 | $29.06 | N/A | 5.3x |
Frequently Asked Questions About RYTM
What is RYTM's forward P/E ratio?
Rhythm Pharmaceuticals has a forward P/E ratio of 333.3x.
What is RYTM's price to sales ratio?
Rhythm Pharmaceuticals has a price to sales ratio of 26.4x.
RYTM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors